ACET Key Statistics, Chart & Performance
The current stock price of ACET is 8.45 USD. In the past month the price increased by 2.64%. In the past year, price decreased by -39.69%.
ACET Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ACET. When comparing the yearly performance of all stocks, ACET is a bad performer in the overall market: 91.27% of all stocks are doing better.
ACET Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ACET. While ACET has a great health rating, there are worries on its profitability.
ACET Financial Highlights
Over the last trailing twelve months ACET reported a non-GAAP Earnings per Share(EPS) of -15.36. The EPS decreased by -798.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -72.53% | ||
| ROE | -88.63% | ||
| Debt/Equity | 0 |
ACET Forecast & Estimates
13 analysts have analysed ACET and the average price target is 101.59 USD. This implies a price increase of 1102.27% is expected in the next year compared to the current price of 8.45.
ACET Ownership
About ACET
Company Profile
Adicet Bio Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boston, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2018-01-26. Adicet Bio, Inc. is a clinical-stage biotechnology company. The company is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases. ADI-001 contains an anti-CD20 CAR that has a proprietary antigen-binding domain that recognizes a region of CD20 distinct from that recognized by rituximab. Its pipeline also includes ADI-270, an investigational allogeneic gamma delta CAR T cell therapy targeting CD70 via the CD27-ligand for the treatment of RCC and with potential in other solid tumor and hematological malignancy indications. Its pipeline has additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.
Company Info
ADICET BIO INC
131 Dartmouth Street, 3Rd Floor
Boston MASSACHUSETTS 02116 US
CEO: Chen Schor
Employees: 152
Phone: 16174822333
ADICET BIO INC / ACET FAQ
What does ACET do?
Adicet Bio Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boston, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2018-01-26. Adicet Bio, Inc. is a clinical-stage biotechnology company. The company is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases. ADI-001 contains an anti-CD20 CAR that has a proprietary antigen-binding domain that recognizes a region of CD20 distinct from that recognized by rituximab. Its pipeline also includes ADI-270, an investigational allogeneic gamma delta CAR T cell therapy targeting CD70 via the CD27-ligand for the treatment of RCC and with potential in other solid tumor and hematological malignancy indications. Its pipeline has additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.
Can you provide the latest stock price for ADICET BIO INC?
The current stock price of ACET is 8.45 USD. The price decreased by -1.05% in the last trading session.
What is the dividend status of ADICET BIO INC?
ACET does not pay a dividend.
What is the ChartMill technical and fundamental rating of ACET stock?
ACET has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the market cap for ADICET BIO INC?
ADICET BIO INC (ACET) has a market capitalization of 1.30B USD. This makes ACET a Small Cap stock.